ReviewFrontiers in endocrinology2023
From gut to placenta: understanding how the maternal microbiome models life-long conditions.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Marked Third-Trimester Placental Thickening Is Associated with Maternal Infectious, Hormonal, and Metabolic Burden: A Matched Case-Control Study.Journal of clinical medicine · 2026Article
- The Maternal Microbiome in Pregnancy: From Physiological Changes to Dysbiosis and Obstetrical Complications-Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- The maternal and infant gut microbiome: implications for pregnancy outcomes, immune development, and health in the first 1000 days.Journal of translational medicine · 2026Review
- Early-Life β-Lactam Exposure and the Developing Microbiome: Clinical Relevance and Controversies.Microorganisms · 2026Review
- Structural and functional characterization of the gut microbiota in women with early pregnancy loss in Northwest China.Frontiers in microbiology · 2026Article
- Gut and Gastric Dysbiosis in Hyperemesis Gravidarum: A Scoping Review of Microbiome-Targeted Evidence and Translational Pathways.International journal of women's health · 2026Review
- Gut-placenta axis: gut microbiota metabolites may play a role in regulating maternal-fetal immune tolerance and the pathogenesis of adverse pregnancy outcomes.Frontiers in immunology · 2026Review
- Maternal milk fat globule membrane enriched gutGut microbes · 2025Article
- Does the Maternal Gut Microbiome Influence the Outcome of Perinatal Asphyxia?Antioxidants (Basel, Switzerland) · 2025Review
- Multiple perinatal characteristics affect the association between maternal diabetes status and early neonatal gut microbiota.mSphere · 2025Article
- Barrier genes are associated with preterm birth.Frontiers in medicine · 2025Article
- The gut-placenta axis in preeclampsia: unraveling the regulatory network and clinical prospects in pathogenesis.Frontiers in cellular and infection microbiology · 2025Review
- Review
- Should Pregnant Women Consume Probiotics to Combat Endocrine-Disrupting Chemical-Induced Health Risks to Their Unborn Offspring?Biomedicines · 2024Review
- Placental Epigenome Impacts Fetal Development: Effects of Maternal Nutrients and Gut Microbiota.Nutrients · 2024Review
- Decoding the Gut Microbiota-Gestational Diabetes Link: Insights from the Last Seven Years.Microorganisms · 2024Review
- The Role ofJournal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microbiome -defined as the microbiota (bacteria, archaea, lower and higher eukaryotes), their genomes, and the surrounding environmental conditions- has a well-described range of physiological functions. Thus, an imbalance of the microbiota composition -dysbiosis- has been associated with pregnancy complications or adverse fetal outcomes. Although there is controversy about the existence or absence of a microbiome in the placenta and fetus during healthy pregnancy, it is known that gut microbiota can produce bioactive metabolites that can enter the maternal circulation and may be actively or passively transferred through the placenta. Furthermore, the evidence suggests that such metabolites have some effect on the fetus. Since the microbiome can influence the epigenome, and modifications of the epigenome could be responsible for fetal programming, it can be experimentally supported that the maternal microbiome and its metabolites could be involved in fetal programming. The developmental origin of health and disease (DOHaD) approach looks to understand how exposure to environmental factors during periods of high plasticity in the early stages of life (e.g., gestational period) influences the program for disease risk in the progeny. Therefore, according to the DOHaD approach, the influence of maternal microbiota in disease development must be explored. Here, we described some of the diseases of adulthood that could be related to alterations in the maternal microbiota. In summary, this review aims to highlight the influence of maternal microbiota on both fetal development and postnatal life, suggesting that dysbiosis on this microbiota could be related to adulthood morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.